A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Renal Insufficiency, Healthy. SEO and diligence focus: LY3502970, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.